| Medical and Health Sciences | Lifetime | 914 | US 474 | 99.96 |
| Pulmonary and Respiratory Medicine | Lifetime | 19 | US 14 | 99.97 |
| Oncology | Lifetime | 309 | US 177 | 99.49 |
| Pathology and Forensic Medicine | Lifetime | 285 | US 139 | 98.96 |
| Cancer Research | Lifetime | 240 | US 127 | 98.61 |
| Medical Genetics | Lifetime | 906 | US 454 | 88.32 |
| Pulmonary and Respiratory Medicine | 2021-2025 | 239 | US 75 | 98.05 |
| Cancer Research | 2021-2025 | 202 | US 72 | 89.40 |
| Oncology | 2021-2025 | 595 | US 261 | 91.26 |
| Sarcoma Diagnosis and Treatment | Lifetime | 5 | US 4 | 99.96 |
| Cancer Genomics and Diagnostics | Lifetime | 9 | US 6 | 99.95 |
| Lung Cancer Treatments and Mutations | Lifetime | 13 | US 9 | 99.94 |
| Cardiac tumors and thrombi | Lifetime | 22 | US 12 | 99.73 |
| Renal and related cancers | Lifetime | 61 | US 43 | 99.52 |
| Lung Cancer Research Studies | Lifetime | 90 | US 51 | 99.55 |
| Medical Imaging and Pathology Studies | Lifetime | 104 | US 53 | 99.20 |
| Colorectal Cancer Treatments and Studies | Lifetime | 129 | US 63 | 99.54 |
| Lymphoma Diagnosis and Treatment | Lifetime | 190 | US 95 | 99.39 |
| Tumors and Oncological Cases | Lifetime | 65 | US 45 | 99.10 |
| Cancer-related gene regulation | Lifetime | 232 | US 119 | 98.55 |
| Vascular Tumors and Angiosarcomas | Lifetime | 72 | US 34 | 98.87 |
| HER2/EGFR in Cancer Research | Lifetime | 238 | US 116 | 98.95 |
| Renal cell carcinoma treatment | Lifetime | 340 | US 189 | 98.44 |
| Genetic factors in colorectal cancer | Lifetime | 438 | US 207 | 98.40 |
| Neuroblastoma Research and Treatments | Lifetime | 316 | US 161 | 98.19 |
| Chromatin Remodeling and Cancer | Lifetime | 71 | US 38 | 97.81 |
| Occupational and environmental lung diseases | Lifetime | 157 | US 69 | 98.01 |
| Cancer-related Molecular Pathways | Lifetime | 494 | US 284 | 98.29 |
| Bone Tumor Diagnosis and Treatments | Lifetime | 433 | US 214 | 97.34 |
| PI3K/AKT/mTOR signaling in cancer | Lifetime | 549 | US 303 | 95.99 |
| Cancer Mechanisms and Therapy | Lifetime | 982 | US 371 | 91.70 |
| Histiocytic Disorders and Treatments | Lifetime | 446 | US 211 | 90.39 |
| Cancer Genomics and Diagnostics | 2021-2025 | 148 | US 76 | 98.88 |
| Lung Cancer Treatments and Mutations | 2021-2025 | 208 | US 82 | 98.63 |
| Sarcoma Diagnosis and Treatment | 2021-2025 | 423 | US 160 | 92.90 |
| Genetic factors in colorectal cancer | 2021-2025 | 531 | US 184 | 91.32 |
| Medical Imaging and Pathology Studies | 2021-2025 | 226 | US 80 | 88.68 |
| Occupational and environmental lung diseases | 2021-2025 | 264 | US 73 | 86.83 |
| Pleural and Pulmonary Diseases | 2021-2025 | 670 | US 141 | 76.72 |
| PI3K/AKT/mTOR signaling in cancer | 2021-2025 | 408 | US 142 | 73.44 |
| Cancer-related Molecular Pathways | 2021-2025 | 850 | US 266 | 73.49 |
| Soft tissue tumor case studies | 2021-2025 | 386 | US 134 | 65.93 |
| Chromatin Remodeling and Cancer | 2021-2025 | 615 | US 251 | 63.10 |
